Worth a look, but always be concerned with no increase in cash flow and marginal increase in sales volumes. Rest of revenue all R&D rebate and FV increase on Bio Assets. How long before they become CF+ and is their a CR in the wings given the feasibility study underway to develop an onshore establishment?
Note from auditor in the financials:
Inherent Material Uncertainty Regarding Valuation of inventory of Biological Assets and harvestedAbalone
Without qualification to the conclusion expressed above, attention is drawn to the following matter:As referred to in Note 8 to the financial statements, biological assets are carried at a value of$8,624,331 (current: $3,493,160; and non-current $5,131,171). The biological assets include liveabalone on abitats, which are measured at fair value less costs to sell. Estimating the fair value is acomplex process involving a number of judgements and estimates regarding various inputs (referalso to Note 2(c)).
Because of the inherent uncertainty associated with the valuation of the biological assets due to theestimates and judgements, as well as the sample size selected for the stocktake, the number ofabalone, their size, biomass, mortality rates and absence of an active market during the growthphase, the carrying value of the biological assets may differ from their realisable value.
Similarly, as the valuation of the harvested abalone is derived from the valuation parameters asoutlined above, their carrying value may differ from the realisable value.
Expand
